Table 1.
The clinical trials of anti-miR miRNA inhibitors
| Clinical trial | |||||
|---|---|---|---|---|---|
| Drug name | miRNA | Diseases/disorders | Number | Phase | Status (Year) |
| Miravirsen (SPC3649) | miR-122 | Hepatitis C | NCT00688012 | I | Completed (2009) |
| NCT00979927 | I | Completed (2011) | |||
| NCT01646489 | I | Completed (2012) | |||
| NCT01200420 | II | Completed (2012) | |||
| NCT01727934 | II | Unknown (2014) | |||
| NCT01872936 | II | Unknown (2014) | |||
| pSil-miR200c/PMIS miR200a | miR-200a/c | Tooth Extraction Status Nos | NCT02579187 | I | Withdrawn (2019) |
| RG-125 (AZD4076) | miR-103/107 | Type 2 diabetes mellitus with non-alcoholic fatty liver disease | NCT02826525 | I | Completed (2019) |
| Non-alcoholic Steatohepatitis | NCT02612662 | I | Active | ||
| MRG-110 (S95010) | miR-92 | Wound healing | NCT03603431 | I | Completed (2019) |
| Cardiovascular Diseases | NCT03494712 | I | Completed (2020) | ||
| CDR132L | miR-132 | Heart Failure | NCT04045405 | I | Completed (2020) |
| Cobomarsen (MRG-106) | miR-155 | Lymphoma; Mycosis Fungoides; Leukemia | NCT02580552 | I | Completed (2020) |
| Cutaneous T-Cell Lymphoma/Mycosis Fungoides | NCT03837457 | II | Terminated (2020) | ||
| NCT03713320 | II | Terminated (2020) | |||
| Lademirsen (RG-012) | miR-21 | Alport Syndrome | NCT03373786 | I | Completed (2019) |
| NCT02855268 | II | Recruiting | |||
| RGLS4326 | miR-17 | Polycystic Kidney Disease, Autosomal Dominant | NCT04536688 | I | Completed (2021) |
| LNA-i-miR-221 | miR-221 | Multiple Myeloma, Refractory; Hepatocarcinoma; Advanced Solid Tumor | NCT04811898 | I | Recruiting |
Notes. Information taken from https://clinicaltrials.gov